Medtronic PLC’s recent decision to buy Stimgenics appears to be justified by the results of a clinical trial evaluating Medtronic’s Intellis spinal cord stimulation system programmed with Stimgenics’ differential target multiplexed (DTM) waveform to treat chronic back pain.
On 21 January, Medtronic announced that three-month results from the 94-patient randomized trial showed statistically significant and superior back pain relief with DTM compared to conventional spinal cord stimulation....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?